What is Erste Group Bank’s Forecast for NVO FY2026 Earnings?

Novo Nordisk A/S (NYSE:NVO) – Investment analysts at Erste Group Bank reduced their FY2026 earnings estimates for shares of Novo Nordisk A/S in a note issued to investors on Tuesday, September 8th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $3.43 per share for the year, down from their prior forecast of $3.46. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.45 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.32 EPS.

Several other equities analysts have also weighed in on the stock. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday. BMO Capital Markets reaffirmed a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Finally, Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S Trading Up 0.9%

Shares of Novo Nordisk A/S stock opened at $43.47 on Monday. The firm has a market cap of $194.10 billion, a PE ratio of 10.63, a P/E/G ratio of 1.45 and a beta of 0.74. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a fifty day moving average price of $47.37 and a 200-day moving average price of $43.71.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.The business had revenue of $11.98 billion during the quarter.

Hedge Funds Weigh In On Novo Nordisk A/S

Several hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Novo Nordisk A/S by 2,414.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock valued at $14,280,000 after acquiring an additional 286,034 shares in the last quarter. Trust Co. of Vermont purchased a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $1,250,000. Burkett Asset Management Ltd bought a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $1,823,000. Myriad Asset Management Advisors LLC bought a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $1,846,000. Finally, Pine Valley Investments Ltd Liability Co purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at $2,324,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is currently 19.80%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy wins China MASH approval: China approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 receptor agonist approved there for the liver disease. The decision expands Wegovy’s addressable market beyond obesity and cardiovascular care and could create an additional long-term growth opportunity. Novo Nordisk Expands Wegovy’s Reach with China MASH Approval
• Positive Sentiment: Oral obesity-drug opportunity remains a potential catalyst: Coverage indicates Novo’s Wegovy pill, launched earlier in 2026, has received a favorable market response, potentially helping the company compete with Eli Lilly’s oral product and regain obesity-market momentum. Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
• Neutral Sentiment: Corporate rebrand targets a turnaround: Novo Nordisk will use “Novo” as its everyday operating name while retaining its legal name, alongside a new “Lasting Health Starts Now” slogan and “The Novo Way” cultural framework. Management says the changes are intended to improve focus, speed and relevance, but they do not directly change earnings or products. Novo Nordisk rebrands to Novo, unveils corporate changes as it fights for obesity market share
• Positive Sentiment: Share repurchases provide support: Novo continues a repurchase program of up to DKK 15 billion over 12 months, which could support per-share value and signal management confidence. Novo Nordisk A/S – share repurchase programme
• Negative Sentiment: Analyst downgrade highlights major risks: Morgan Stanley cut NVO to Underweight, citing muted growth, patent exposure and intensifying competition from Eli Lilly. Investors remain concerned that Novo must deliver new blockbuster products after a sharp prior decline in the stock. Will Morgan Stanley’s NVO downgrade deepen patent and rival woes?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.